文献速递胸部肿瘤

阿得贝利单抗(SHR-1316)联合化疗作为可切除II至III期非小细胞肺癌围手术期治疗:一项开放标签、多中心、1b期试验

Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial.
PubMed 文献 · J Thorac Oncol · 2022-10-01

该1b期试验评估阿得贝利单抗联合白蛋白结合型紫杉醇和卡铂用于可切除II至III期无驱动基因非小细胞肺癌的围手术期治疗。37例患者接受新辅助治疗后,51.4%达到主要病理缓解,29.7%达到病理完全缓解,78.4%发生≥3级治疗相关不良事件,未发生治疗相关死亡。

要点

  • 37例可切除II-III期NSCLC患者接受阿得贝利单抗联合白蛋白结合型紫杉醇和卡铂新辅助治疗,34例(91.9%)接受手术。
  • 主要病理缓解率为51.4%(95%CI 35.9-66.6),病理完全缓解率为29.7%(95%CI 17.5-45.8)。
  • ≥3级治疗相关不良事件发生率为78.4%,治疗相关严重不良事件为24.3%,无治疗相关死亡。

核心结论

  • 阿得贝利单抗联合白蛋白结合型紫杉醇和卡铂围手术期治疗可使可切除II至III期NSCLC患者获得较高比例的主要病理缓解和高可切除率,毒性可控。
  • 基于1b期结果,已启动3期试验。

研究设计与样本

  • 开放标签、多中心、1b期试验,纳入可切除II至III期无驱动基因NSCLC患者。
  • 患者术前接受3个周期新辅助治疗:阿得贝利单抗20 mg/kg第1天静脉给药,白蛋白结合型紫杉醇100 mg/m2第1、8、15天,卡铂曲线下面积5 mg/mL/min第1天,每21天一个周期。
  • 术后接受16个周期阿得贝利单抗20 mg/kg第1天辅助治疗,每3周一次。
  • 主要终点为盲法独立病理审查评估的主要病理缓解。
  • 共37例患者入组并接受计划的新辅助治疗。

主要发现

  • 34例患者(91.9%)接受了手术。
  • 截至2022年1月25日数据截止,37例中19例(51.4%,95%CI 35.9-66.6)达到主要病理缓解。
  • 11例(29.7%,95%CI 17.5-45.8)达到病理完全缓解。
  • 26例(70.3%,95%CI 54.2-82.5)达到客观缓解(依据RECIST 1.1)。
  • 12个月无事件生存率为77.8%(95%CI 54.1-90.3)。

临床怎么用

  • 作者认为,阿得贝利单抗联合白蛋白结合型紫杉醇和卡铂围手术期治疗使可切除II至III期NSCLC患者获得较高比例的主要病理缓解和高可切除率,毒性可控。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study evaluated adebrelimab (a programmed death-ligand 1 antibody) plus nab-paclitaxel and carboplatin as perioperative treatment for resectable NSCLC. METHODS: Eligible patients had resectable stage II to III NSCLCs without driver gene. Patients received neoadjuvant treatment with three cycles of intravenous adebrelimab (20 mg/kg on day 1), nab-paclitaxel (100 mg/m2 on days 1, 8, and 15), and carboplatin (area under the curve 5 mg/mL per min on day 1), of each 21-day cycle before surgical resection, and followed by 16 cycles of adebrelimab (20 mg/kg on day 1 in 3 wk) adjuvant treatment. The primary end point was major pathologic response (MPR) per blinded independent pathologic review. RESULTS: A total of 37 patients were enrolled and received planned neoadjuvant therapy. There were 34 patients (91.9%) who underwent surgery. As of data cutoff on January 25, 2022, 19 of the 37 patients (51.4%, 95% confidence interval [CI]: 35.9-66.6) achieved MPR per blinded independent pathologic review and 11 patients (29.7%, 95% CI: 17.5-45.8) achieved pathologic complete response. Furthermore, 26 patients (70.3%, 95% CI: 54.2-82.5) had an objective response per Response Evaluation Criteria in Solid Tumors version 1.1. The 12-month event-free survival rate was 77.8% (95% CI: 54.1-90.3). In addition, 29 patients (78.4%) had grade greater than or equal to three treatment-related adverse events (AEs) and nine (24.3%) had treatment-related serious AEs. No treatment-related deaths occurred. Grade greater than or equal to three surgery-related AEs within 30 or 90 days after surgery were both reported in five patients (14.7%). CONCLUSIONS: Adebrelimab plus nab-paclitaxel and carboplatin as perioperative therapy led to a substantial proportion of MPR and high resectability, with manageable toxicities. On the basis of the phase 1b results, phase 3 trial was initiated.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yan W, Zhong WZ, Liu YH, et al. Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial. J Thorac Oncol. 2022. PMID: 36191882. doi:10.1016/j.jtho.2022.09.222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。